Chondrosarcoma Pipeline Outlook Report 2025: MOA, Companies, Companies, Clinical Trials, Expanding Therapeutic Classes, and Future Market Impact Revealed

DelveInsight's "Chondrosarcoma Pipeline Insight 2025" report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Chondrosarcoma pipeline landscape. It covers the Chondrosarcoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chondrosarcoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Chondrosarcoma pipeline products in this space.

Explore our latest breakthroughs in Chondrosarcoma Research. Learn more about our innovative pipeline today! @ Chondrosarcoma Pipeline Outlook [https://www.delveinsight.com/sample-request/chondrosarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Chondrosarcoma Pipeline Report

* On 18 November 2025, the Italian Sarcoma Group conducted a phase II clinical study to explore the activity of trabectedin in a population of patients aged greater than or equal to 16 years with progressive, advanced (locally advanced or metastatic).
* On 12 November 2025, Servier Bio-Innovation LLC announced a phase 3 study of Ivosidenib in Participants greater than or equal to 18 Years of Age With Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen.
* DelveInsight's Chondrosarcoma pipeline report depicts a robust space with 15+ active players working to develop 15+ pipeline therapies for Chondrosarcoma treatment.
* The leading Chondrosarcoma Companies such as PharmaMar, Inhibrx, Shanghai Junshi Bioscience Co. Ltd., Hutchmed, Atlanthera and others.
* Promising Chondrosarcoma Therapies such as Pazopanib, Trabectedin, INBRX-109, AG-120, IPI-926, Perifosine, Loperamide, Allopurinol, Enasidenib and others.

Stay informed about the cutting-edge advancements in Chondrosarcoma treatments. Download for updates and be a part of the revolution @ Chondrosarcoma Clinical Trials Assessment [https://www.delveinsight.com/sample-request/chondrosarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Chondrosarcoma Pipeline Report provides a disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The Chondrosarcoma Pipeline Report also highlights the unmet needs with respect to Chondrosarcoma.

Chondrosarcoma Overview

Chondrosarcoma (CS) is a group of bone tumors that are made up of cells that make too much cartilage. Cartilage is the specialized, gristly connective tissue that is present in adults and the tissue from which most bones develop. Cartilage plays an important role in the growth process. There are many different types of cartilage that are present throughout the body. Chondrosarcoma primarily affects the cartilage cells of the femur (thighbone), arm, pelvis, or knee. Although less often, other areas (such as the ribs) may be affected. Chondrosarcomas are malignant cartilaginous neoplasms with diverse morphological features and clinical behavior. They account for about 20% of all primary malignant tumors of the bone. They usually arise in the pelvis or long bones.

Chondrosarcoma Emerging Drugs Profile

* Trabectedin: PharmaMar

Trabectedin, also known as ecteinascidin 743 or ET-743l, or commercially where it is approved as Yondelis Registered is a synthetic compound derived from the colonial sea squirt Ecteinascidia turbinata. Trabectedin inhibits active transcription of protein-coding genes through binding to promoters and irreversibly stalling elongating RNA polymerase II on the DNA template, thereby leading to double-stranded DNA breaks and apoptosis. Trabectedin (Yondelis) is an anti-tumor agent of marine origin discovered in the caribbean tunicate, ecteinascidia turbinata. It is formulated as lyophilized powder for solution for injection for intravenous route of administration. Yondelis is indicated for the treatment of adult patients with advanced soft tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents. Currently the drug is in Phase II stage of Clinical trial evaluation for the treatment of Mesenchymal Chondrosarcoma.

* INBRX-109: Inhibrx

INBRX-109 is a precisely engineered tetravalent single domain antibody (sdAb)-based therapeutic candidate that agonizes death receptor 5 (DR5) to induce tumor selective programmed cell death. INBRX-109, is a tetravalent DR5 agonistic antibody, designed to exploit tumor-biased direct cell death induction by DR5 activation in numerous cancer types. With a valency of four, it has the ability to potently agonize DR5 through efficient receptor clustering, causing cell death, but by way of the sdAb platform, also eliminates recognition by pre-existing anti-drug antibodies (ADAs) to lessen the potential for hyper-clustering. In preclinical studies, INBRX-109 led to antitumor activity in vitro and in patient-derived xenograft models, with minimal hepatotoxicity. Currently the drug is in Phase II stage of Clinical trial evaluation for the treatment of Chondrosarcoma.

* JS001sc: Shanghai Junshi Bioscience Co., Ltd.

JS001sc injection is a subcutaneous injection formulation developed by Junshi Biosciences on the basis of the marketed product toripalimab. JS001sc targets PD-1, binds to PD-1 with high affinity, and selectively blocks the binding of PD-1 to the ligands PD-L1 and PD-L2, thereby activating T lymphocytes and improving lymphocyte proliferation and cytokine secretion. The pre-clinical in vivo pharmacodynamics shows that JS001sc exhibits significant anti-tumor effect in animal models by subcutaneous injection. At certain dose level, the anti-tumor effect of JS001sc administered by subcutaneous injection is comparable to that of toripalimab administered by intravenous injection, with no significant difference. In addition, animals have a good tolerance to JS001sc. So far, JS001sc has received the clinical trial approval from the NMPA. Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Chondrosarcoma.

* HMPL-306: Hutchmed

HMPL-306, is an investigational drug being developed by Hutchmed. HMPL-306 is an investigational novel selective small molecule dual inhibitor of isocitrate dehydrogenase (IDH) 1 and 2 mutations. IDH1 and IDH2 mutations have been implicated as drivers of certain hematological malignancies, gliomas and solid tumors, particularly among acute myeloid leukemia patients. Cytoplasmic mutant IDH1 and mitochondrial mutant IDH2 have been known to switch to the other form when targeted by an inhibitor of IDH1 mutant alone or IDH2 mutant alone. Cancer patients harboring either IDH mutation have been known to develop resistance to therapies that target IDH1 or IDH2 through isoform switching. Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Chondrosarcoma.

The Chondrosarcoma Pipeline Report provides insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Chondrosarcoma with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chondrosarcoma Treatment.
* Chondrosarcoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Chondrosarcoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chondrosarcoma market.

Learn more about Chondrosarcoma Drugs opportunities in our groundbreaking Chondrosarcoma research and development projects @ Chondrosarcoma Unmet Needs [https://www.delveinsight.com/sample-request/chondrosarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Chondrosarcoma Companies

PharmaMar, Inhibrx, Shanghai Junshi Bioscience Co. Ltd., Hutchmed, Atlanthera and others.

Chondrosarcoma Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Ophthalmic
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal

Chondrosarcoma Products have been categorized under various Molecule types such as

* Oligonucleotide
* Peptide
* Small molecule

Discover the latest advancements in Chondrosarcoma treatment by visiting our website. Stay informed about how we're transforming the future of Neurology @ Chondrosarcoma Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/chondrosarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Chondrosarcoma Pipeline Report

* Coverage- Global
* Chondrosarcoma Companies- PharmaMar, Inhibrx, Shanghai Junshi Bioscience Co. Ltd., Hutchmed, Atlanthera and others.
* Chondrosarcoma Therapies- Pazopanib, Trabectedin, INBRX-109, AG-120, IPI-926, Perifosine, Loperamide, Allopurinol, Enasidenib and others.
* Chondrosarcoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Chondrosarcoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Chondrosarcoma Pipeline on our website, @ Chondrosarcoma Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/chondrosarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Chondrosarcoma: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Chondrosarcoma- DelveInsight's Analytical Perspective
* Mid Stage Products (Phase II)
* Trabectedin: PharmaMar
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase I/II)
* Seclidemstat: Salarius Pharmaceuticals, LLC
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* JS001sc: Shanghai Junshi Bioscience Co., Ltd.
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Ifosfamide: Atlanthera
* Drug profiles in the detailed report.....
* Inactive Products
* Chondrosarcoma Key Companies
* Chondrosarcoma Key Products
* Chondrosarcoma- Unmet Needs
* Chondrosarcoma- Market Drivers and Barriers
* Chondrosarcoma- Future Perspectives and Conclusion
* Chondrosarcoma Analyst Views
* Chondrosarcoma Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=chondrosarcoma-pipeline-outlook-report-2025-moa-companies-companies-clinical-trials-expanding-therapeutic-classes-and-future-market-impact-revealed]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/chondrosarcoma-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.